Can Fite Biopharma Ltd
CANF0.212USD
+0.032+17.47%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
840.30MMarket Cap
LossP/E TTM
More Details of Can Fite Biopharma Ltd Company
Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Can Fite Biopharma Ltd Info
Ticker SymbolCANF
Company nameCan Fite Biopharma Ltd
IPO dateSep 22, 2005
CEOFishman (Pnina)
Number of employees5
Security typeDepository Receipt
Fiscal year-endSep 22
Address10 Bareket Street, Kiryat Matalon
CityPETAH TIKVA
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryIsrael
Postal code49170
Phone97239241114
Websitehttps://www.canfite.com/
Ticker SymbolCANF
IPO dateSep 22, 2005
CEOFishman (Pnina)
Company Executives of Can Fite Biopharma Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Yaacov Goldman
Mr. Yaacov Goldman
Independent Director
Independent Director
--
--
Mr. Guy Regev
Mr. Guy Regev
Independent Director
Independent Director
--
--
Dr. Abraham Sartani, M.D.
Dr. Abraham Sartani, M.D.
Independent Director
Independent Director
--
--
Dr. Ilan Cohen
Dr. Ilan Cohen
Chairman of the Board
Chairman of the Board
--
--
Dr. Pnina Fishman, Ph.D.
Dr. Pnina Fishman, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Motti Farbstein
Mr. Motti Farbstein
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Dr. Sari Fishman, Ph.D.
Dr. Sari Fishman, Ph.D.
Vice President - Business Development
Vice President - Business Development
--
--
Mr. Yoseph Borenstein
Mr. Yoseph Borenstein
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Yaacov Goldman
Mr. Yaacov Goldman
Independent Director
Independent Director
--
--
Mr. Guy Regev
Mr. Guy Regev
Independent Director
Independent Director
--
--
Dr. Abraham Sartani, M.D.
Dr. Abraham Sartani, M.D.
Independent Director
Independent Director
--
--
Dr. Ilan Cohen
Dr. Ilan Cohen
Chairman of the Board
Chairman of the Board
--
--
Dr. Pnina Fishman, Ph.D.
Dr. Pnina Fishman, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Motti Farbstein
Mr. Motti Farbstein
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Sabby Management, LLC
5.37%
Rhumbline Advisers Ltd. Partnership
0.22%
Abalone Asset Management Ltd.
0.09%
BNP Paribas Securities Corp. North America
0.06%
Bogart Wealth, LLC
0.06%
Other
94.20%
Shareholders
Shareholders
Proportion
Sabby Management, LLC
5.37%
Rhumbline Advisers Ltd. Partnership
0.22%
Abalone Asset Management Ltd.
0.09%
BNP Paribas Securities Corp. North America
0.06%
Bogart Wealth, LLC
0.06%
Other
94.20%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
5.37%
Investment Advisor
0.43%
Research Firm
0.12%
Hedge Fund
0.04%
Other
94.03%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
30
1.56M
6.39%
--
2025Q3
33
1.56M
9.88%
+633.60K
2025Q2
31
928.79K
6.69%
+773.65K
2025Q1
30
155.14K
8.36%
-710.63K
2024Q4
28
138.24K
8.71%
-639.91K
2024Q3
26
778.14K
10.55%
+126.51K
2024Q2
26
651.74K
10.05%
+134.05K
2024Q1
24
517.69K
5.29%
+253.94K
2023Q4
29
283.94K
2.08%
+216.17K
2023Q3
28
67.77K
12.19%
+13.03K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Sabby Management, LLC
779.74K
4.57%
+779.74K
--
Jun 30, 2025
Rhumbline Advisers Ltd. Partnership
57.58K
0.34%
+19.31K
+50.47%
Jun 30, 2025
Abalone Asset Management Ltd.
23.81K
0.14%
-16.19K
-40.48%
Jun 30, 2024
BNP Paribas Securities Corp. North America
17.59K
0.1%
-5.00K
-22.14%
Jun 30, 2025
Morgan Stanley & Co. LLC
9.91K
0.06%
-13.30K
-57.30%
Jun 30, 2025
CAPTRUST Financial Advisors
11.38K
0.07%
+741.00
+6.97%
Jun 30, 2025
Two Sigma Investments, LP
16.06K
0.09%
+16.06K
--
Jun 30, 2025
MainStreet Advisors
3.00K
0.02%
--
--
Jun 30, 2025
Wells Fargo Advisors
2.70K
0.02%
--
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
Date
Type
Ratio
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
FAQs
Who are the top five shareholders of Can Fite Biopharma Ltd?
The top five shareholders of Can Fite Biopharma Ltd are:
Sabby Management, LLC holds 779.74K shares, accounting for 4.57% of the total shares.
Rhumbline Advisers Ltd. Partnership holds 57.58K shares, accounting for 0.34% of the total shares.
Abalone Asset Management Ltd. holds 23.81K shares, accounting for 0.14% of the total shares.
BNP Paribas Securities Corp. North America holds 17.59K shares, accounting for 0.10% of the total shares.
Morgan Stanley & Co. LLC holds 9.91K shares, accounting for 0.06% of the total shares.
Sabby Management, LLC holds 779.74K shares, accounting for 4.57% of the total shares.
Rhumbline Advisers Ltd. Partnership holds 57.58K shares, accounting for 0.34% of the total shares.
Abalone Asset Management Ltd. holds 23.81K shares, accounting for 0.14% of the total shares.
BNP Paribas Securities Corp. North America holds 17.59K shares, accounting for 0.10% of the total shares.
Morgan Stanley & Co. LLC holds 9.91K shares, accounting for 0.06% of the total shares.
What are the top three shareholder types of Can Fite Biopharma Ltd?
The top three shareholder types of Can Fite Biopharma Ltd are:
Sabby Management, LLC
Rhumbline Advisers Ltd. Partnership
Abalone Asset Management Ltd.
Sabby Management, LLC
Rhumbline Advisers Ltd. Partnership
Abalone Asset Management Ltd.
How many institutions hold shares of Can Fite Biopharma Ltd (CANF)?
As of 2025Q4, 30 institutions hold shares of Can Fite Biopharma Ltd, with a combined market value of approximately 1.56M, accounting for 6.39% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -3.49%.
What is the biggest source of revenue for Can Fite Biopharma Ltd?
In --, the -- business generated the highest revenue for Can Fite Biopharma Ltd, amounting to -- and accounting for --% of total revenue.
